| Company/Division name | Horizon Therapeutics |
| Parent company | Horizon Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Country(ies) from which reshored: | Ireland |
| City reshored to: | San Francisco |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | medicines |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D) |
